EFTUD2

Across TCGA pan-cancer cohorts, EFTUD2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of EFTUD2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where EFTUD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types EFTUD2 is over-expressed in tumor.

COAD, HNSC, and CCRCC are the cancer types where EFTUD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EFTUD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	III,IV	+0.418	<.001	12	view →
HNSC	Male	IV	+0.272	<.001	11	view →
CCRCC	Male	III,IV	+0.211	<.001	11	view →
LSCC	Male	II,III,IV	+0.426	<.001	9	view →
LUAD	Female	All	+0.283	<.001	9	view →
PDAC	Male	All	+0.235	<.001	6	view →
OV	All	All	+0.415	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

EFTUD2–COAD

Open the COAD breakdown →